Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
You may also be interested in...
Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align
Proposed decision withholds Medicare coverage from current and future amyloid-directed monoclonal antibody drugs for Alzheimer’s disease unless patients are enrolled in a randomized clinical trial.
With CMS draft decision expected next month on amyloid-clearing antibodies for Alzheimer’s, Biogen slashes Aduhem’s price 50% to $28,200 per year. Move reverses another aspect of the approval that drew criticism, including the expansive label and long horizon for confirmatory data.
The Alzheimer’s drug’s price was cut to $28,200 per year just one month before CMS is expected to issue a draft national coverage determination for amyloid-clearing antibodies, raising questions about the timing.